ARL4C and pancreatic neoplasm: Inhibiting ARL4C (siRNA, antisense oligonucleotide, ribozyme, and siRNA expression vector) for the treatment of cancer (such as liver cancer, colon cancer, lung cancer, tongue cancer, and pancreatic cancer) was investigated by Osaka University NUC (patent number: JP06436477B2 and WO2020050307A1).